Zepbound

Eli Lilly's 56% revenue growth and 156% EPS surge in Q1 2026, driven by GLP-1 dominance and oral formulation expansion, signal continuing upside potential for investors.

Eli Lilly stock near $960 has 26% upside to $1,215 consensus target, driven by blockbuster GLP-1 drugs Mounjaro and Zepbound delivering 60% revenue growth.

Eli Lilly's weight loss drugs deliver explosive growth with Mounjaro up 125% and Zepbound up 80%. New oral drug Foundayo already serves 20,000 patients.

Eli Lilly beat Q1 earnings expectations and raised full-year guidance, driven by blockbuster demand for weight-loss drugs Mounjaro and Zepbound.

Morgan Stanley analyst targets $1,327 for Eli Lilly, citing $45B weight-loss drug sales potential by 2030, implying 52% upside from current $870 levels.

Eli Lilly received FDA approval for Foundayo weight-loss pill in April 2026. With 40%+ growth and premium valuation, stock needs only 20% gain to hit $1 trillion market cap.

Eli Lilly acquires Centessa Pharmaceuticals for $6.3B, gaining neuroscience assets. Stock rises on strong financial footing from weight-loss drug success.

Eli Lilly bets on AI-driven drug discovery alongside its $11B weight loss drug franchise, partnering with Nvidia and Insilico Medicine to build next-generation blockbusters.

$LLY dominates GLP-1 market with strong Mounjaro, Zepbound sales but trades at 40x P/E—well above pharma peers—raising concerns about priced-in perfection.

Eli Lilly's GLP-1 drugs drive 56% of revenues with explosive growth, but 43x P/E valuation leaves no room for disappointment amid intensifying competition and future patent risks.

Eli Lilly commits $3 billion to decade-long China expansion, targeting 141 million diabetics and 600 million overweight adults amid intense domestic competition.

Eli Lilly warns of unidentified impurity in compounded tirzepatide weight loss drugs mixed with vitamin B12, urging FDA recalls and stricter oversight.

Eli Lilly trades at expensive P/E of 44 with meager 0.6% dividend yield despite GLP-1 success. Merck offers better value at P/E 16 and 2.8% yield with 30+ year dividend track record.

Eli Lilly trades at premium 44 P/E despite GLP-1 concentration risks. Novo Nordisk and Pfizer offer higher yields and lower valuations.

Eli Lilly strengthens obesity drug dominance as competitor's treatment fails trials and Lilly launches new monthly-dose Zepbound pen, commanding 60% market share.

Eli Lilly strengthens market position with blockbuster weight-loss drug Zepbound, diversified pipeline, and AI integration, supporting consistent financial performance and shareholder returns.

Eli Lilly's combo therapy of Taltz and Zepbound showed superior results for psoriasis-obesity patients, achieving 27.1% complete skin clearance versus 5.8% for monotherapy.